In summary, this study demonstrates a statistically significant reduced risk of bladder cancer associated with the SNP-inferred NAT2 slow acetylation status, but an increased risk of bladder cancer with the CMR-determined slow acetylation status. This evidence concerns the gene NAT2 and urinary bladder cancer.